PET and Hormone Receptor Ligands in Breast Cancer
Abstract
F-18 labeled estradiol has been found to be useful in the evaluation of estrogen receptor status in patients with breast cancer using PET. To investigate this further, this project's objectives are: To evaluate the use of estrogen-like ligands labeled with positron emitters in preoperatively determining the ER status of breast cancer using PET. Correlate the ER positivity seen on PET imaging with ER positivity found on pathologic analysis of the surgical specimen. This "proof-of-concept" study is a pilot study designed to determine feasibility of PET imaging. If the study is positive, i.e. if more than 70% of ER+ lesions are positive on PET imaging, we will subsequently plan a study with outcome parameters. PET scans will be graded as negative or positive (defined as tumor:normal uptake ratios of >1.5:1) and ER status will also be graded as negative or positive (defined as staining of> 5% tumor cells in an average high power field). Paired t-test comparison of tumor HO and PET findings will be carried out. Gamma well counting will be used to quantify uptake of radioactivity in tumor and normal tissue including serum, and expressed as percent injected dose/gram. Serum estradiol is being measured to observe a possible relationship between serum estradiol levels and targeting of radiotracer.
Document Details
- Document Type
- Technical Report
- Publication Date
- May 01, 2006
- Accession Number
- ADA456204
Entities
People
- Mary Gemignani
Organizations
- Memorial Sloan Kettering Cancer Center